Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

GlaxoSmithKline (GSK) Gets a Buy from Shore Capital

Tipranks - Tipranks - Thu Mar 26, 10:38PM CDT

In a report released yesterday, from Shore Capital reiterated a Buy rating on GlaxoSmithKline. The company’s shares closed yesterday at p2,054.00.

Claim 30% Off TipRanks Premium

The word on The Street in general, suggests a Hold analyst consensus rating for GlaxoSmithKline with a p2,019.00 average price target, representing a -1.70% downside. In a report released on March 24, TipRanks – xAI also reiterated a Buy rating on the stock with a p2,179.00 price target.

See today’s best-performing stocks on TipRanks >>

Based on GlaxoSmithKline’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of p8.62 billion and a net profit of p636 million. In comparison, last year the company earned a revenue of p8.12 billion and had a net profit of p414 million

Based on the recent corporate insider activity of 327 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of GSK in relation to earlier this year.

Read More on GB:GSK:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).